Pharma

Your Article Summary

See Latest Articles

Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to be Presented at the 2008 American Society of Hematology Annual Meeting and Exposition
Cytokinetics, 12/02/08

Cytokinetics, Incorporated announced that an abstract summarizing interim clinical trial data evaluating SB-743921 is scheduled to be presented as a poster presentation at the 2008 American Society of Hematology (ASH) Annual Meeting and Exposition to be held at the Moscone Center in San Francisco, California. SB-743921 is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division, being developed by Cytokinetics under a collaboration with GlaxoSmithKline.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

 See all of Drug Trials